Characterization of the saturation class C 0 ? L?

1987 ◽  
Vol 38 (4) ◽  
pp. 356-361
Author(s):  
V. T. Gavrilyuk
Keyword(s):  
Saturation Class ◽  
Class C

scholarly journals Cloning and Characterization of a Chromosomal Class C β-Lactamase and Its Regulatory Gene in Laribacter hongkongensis

2005 ◽  
Vol 49 (5) ◽  
pp. 1957-1964 ◽  
Author(s):  
Susanna K. P. Lau ◽  
Pak-leung Ho ◽  
Maria W. S. Li ◽  
Hoi-wah Tsoi ◽  
Raymond W. H. Yung ◽  
...  
Keyword(s):  
Genomic Dna ◽  
Southern Hybridization ◽  
Regulatory Gene ◽  
Kinetic Properties ◽  
Restriction Fragments ◽  
Regulatory Systems ◽  
Laribacter Hongkongensis ◽  
Consensus Motifs ◽  
Class C

ABSTRACT Laribacter hongkongensis, a newly discovered bacterium recently shown to be associated with community-acquired gastroenteritis, is generally resistant to most β-lactams except the carbapenems. We describe the cloning and characterization of a novel chromosomal class C β-lactamase and its regulatory gene in L. hongkongensis. Two genes, ampC and ampR, were cloned by inserting restriction fragments of genomic DNA from L. hongkongensis strain HLHK5 into pBK-CMV to give the recombinant plasmid pBK-LHK-5. The ampR and ampC genes and their promoters were divergently oriented, with the ampR gene immediately upstream of the ampC gene and an intercistronic Lys-R motif, typical of inducible ampC-ampR regulatory systems. The deduced amino acid sequence of the cloned AmpC β-lactamase (pI 8.1) contained consensus motifs characteristic of class C β-lactamases but had identities no greater than 46% to known class C β-lactamases. The kinetic properties of this AmpC were also compatible with those of a class C β-lactamase. PCR of 20 clinical isolates of L. hongkongensis, including HLHK5, showed the presence of both ampC and ampR genes in all isolates. Southern hybridization suggested that the ampC gene of HLHK5 was chromosomally encoded. Subcloning experiments showed that the expression of the ampC gene of HLHK5 was regulated by its ampR gene, which acts as a repressor. The β-lactamase characterized from strain HLHK5 was named LHK-5 (gene, bla LHK-5) and represents the first example of AmpC β-lactamase in the β subdivision of proteobacteria.

scholarly journals Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition

2016 ◽  
Vol 60 (5) ◽  
pp. 3183-3186 ◽  
Author(s):  
Sushmita D. Lahiri ◽  
Richard A. Alm
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Binding Pocket ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Content Type ◽  
Class A ◽  
Extended Spectrum ◽  
Class C

ABSTRACTCeftazidime-avibactam has activity againstPseudomonas aeruginosaandEnterobacteriaceaeexpressing numerous class A and class C β-lactamases, although the ability to inhibit many minor enzyme variants has not been established. Novel VEB class A β-lactamases were identified during characterization of surveillance isolates. The cloned novel VEB β-lactamases possessed an extended-spectrum β-lactamase phenotype and were inhibited by avibactam in a concentration-dependent manner. The residues that comprised the avibactam binding pocket were either identical or functionally conserved. These data demonstrate that avibactam can inhibit VEB β-lactamases.

scholarly journals Characterization of the New AmpC β-Lactamase FOX-8 Reveals a Single Mutation, Phe313Leu, Located in the R2 Loop That Affects Ceftazidime Hydrolysis

2013 ◽  
Vol 57 (10) ◽  
pp. 5158-5161 ◽  
Author(s):  
Francisco José Pérez-Llarena ◽  
Frédéric Kerff ◽  
Laura Zamorano ◽  
María Carmen Fernández ◽  
Maria Luz Nuñez ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Kinetic Analysis ◽  
Clinical Strain ◽  
Single Mutation ◽  
Content Type ◽  
E Coli ◽  
Fold Reduction ◽  
Class C

ABSTRACTA novel class C β-lactamase (FOX-8) was isolated from a clinical strain ofEscherichia coli. The FOX-8 enzyme possessed a unique substitution (Phe313Leu) compared to FOX-3. IsogenicE. colistrains carrying FOX-8 showed an 8-fold reduction in resistance to ceftazidime relative to FOX-3. In a kinetic analysis, FOX-8 displayed a 33-fold reduction inkcat/Kmfor ceftazidime compared to FOX-3. In the FOX family of β-lactamases, the Phe313 residue located in the R2 loop affects ceftazidime hydrolysis and alters the phenotype ofE. colistrains carrying this variant.

scholarly journals SEM/EDX Characterization of the Hydration Products of Belite Cements from Class C Coal Fly Ash

2007 ◽  
Vol 0 (0) ◽  
pp. 071005114204002-???
Author(s):  
Sara Goñi ◽  
Ana Guerrero
Keyword(s):  
Fly Ash ◽  
Coal Fly Ash ◽  
Hydration Products ◽  
Class C

scholarly journals Microbiological characterization of VNRX-5236: a broad spectrum β-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended spectrum β-lactamases and serine carbapenemases.

2021 ◽  
Author(s):  
Cassandra L. Chatwin ◽  
Jodie C. Hamrick ◽  
Robert E. L. Trout ◽  
Cullen L. Myers ◽  
Susan M. Cusick ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Clinical Isolates ◽  
Class A ◽  
Extended Spectrum ◽  
Oral Agents ◽  
Class C ◽  
Orally Bioavailable ◽  
Lactamase Inhibitor

There is an urgent need for oral agents to combat resistant gram-negative pathogens. Here we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI) and its orally bioavailable etzadroxil prodrug, VNRX-7145. VNRX-7145 is being developed in combination with ceftibuten, an oral cephalosporin, to combat strains of Enterobacterales expressing extended spectrum β-lactamases (ESBLs) and serine carbapenemases. VNRX-5236 is a reversible covalent inhibitor of serine β-lactamases, with inactivation efficiencies on the order of 104 M−1. sec−1, and prolonged active site residence times (t1/2, 5 to 46 min). The spectrum of inhibition includes Ambler class A ESBLs, class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively). Rescue of ceftibuten by VNRX-5236 (fixed at 4 μg/mL) in isogenic strains of E. coli expressing class A, C or D β-lactamases demonstrated an expanded spectrum of activity relative to oral comparators including investigational penems, sulopenem and tebipenem. VNRX-5236 rescued ceftibuten activity in clinical isolates of Enterobacterales expressing ESBLs (MIC90 = 0.25 μg/mL), KPCs (MIC90 = 1 μg/mL), class C cephalosporinases (MIC90 = 1 μg/mL) and OXA-48-type carbapenemases (MIC90 = 1 μg/mL). Frequency of resistance studies demonstrated a low propensity for recovery of resistant variants at 4× the MIC of the ceftibuten/VNRX-5236 combination. In vivo, whereas ceftibuten alone was ineffective (ED50, >128 mg/kg), ceftibuten/VNRX-7145 administered orally protected mice from lethal septicemia caused by K. pneumoniae producing KPC carbapenemase (ED50, 12.9 mg/kg). The data demonstrate potent, broad-spectrum rescue of ceftibuten activity by VNRX-5236 in clinical isolates of cephalosporin-resistant and carbapenem-resistant Enterobacterales.

Sign in / Sign up

Export Citation Format

Share Document